SecBot SecBot
8-K ·Filed May 12, 2026

KURA

Kura Oncology, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001193125-26-219422
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

KOMZIFTI launch revenue of $5.8M in the first full quarter signals early commercial traction, but the stock will likely trade on upcoming clinical catalysts (EHA June 2026 data for ziftomenib/7+3, ASCO May 2026 darlifarnib data) rather than this quarter's financials. Monitor payer adoption trends and repeat prescription rates for signs of sustained uptake.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.48
T+0 close · May 12, 2026 · via day close
Latest settled
+0.95%
T+60 · $9.57
Vs SPY
−3.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $9.48entry
  2. T+1 · 6mo ago 0.00%α +0.00% · $9.48
  3. T+5 · 6mo ago −5.49%α −4.33% · $8.96
  4. T+20 · 5mo ago −6.54%α −5.93% · $8.86
  5. T+60 · 3mo ago +0.95%α −3.49% · $9.57
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology reported Q1 2026 results with $5.8M in KOMZIFTI product revenue (first full commercial quarter), beating consensus revenue estimates. However, the net loss widened to $73.3M ($0.83/share) vs $57.4M ($0.66/share) in Q1 2025, driven by increased R&D and SG&A costs for the commercial launch and clinical trials. The company maintains a strong cash position of $580.8M plus $180M in anticipated collaboration payments, funding operations into 2028.

Key Financial Metrics

EPS
−$0.83
est −$0.88 · +5.7%
Revenue
$18.3M
est $25.9M · -29.5% · +29.5% YoY
Rating
in line

Key Facts

  • Q1 2026 net product revenue of $5.8M from KOMZIFTI, first full commercial quarter
  • 85 new patient starts and 157 total prescriptions in Q1 2026
  • Net loss of $73.3M ($0.83/share) vs $57.4M ($0.66/share) in Q1 2025
  • Cash and investments of $580.8M as of March 31, 2026, down from $667.2M at year-end 2025
  • R&D expenses of $65.3M, up from $56.0M in Q1 2025, driven by KOMET-017 Phase 3 trials
  • SG&A expenses of $31.6M, up from $22.8M in Q1 2025, reflecting commercialization costs
  • Payer coverage >93% across plans covering >12 million lives
  • Multiple clinical data readouts expected in 2026 across AML combination settings

Financial Impact

Q1 2026 total revenue of $18.3M ($5.8M product + $12.5M collaboration) vs consensus $25.9M; net loss of $73.3M vs consensus loss of $77.0M (EPS $-0.83 vs consensus $-0.88, a 5.7% beat)

revenuenet losscash positionR&D spend

Risk Factors

  • Cash burn rate of ~$86M/quarter implies ~6-7 quarters of runway without additional collaboration milestones
  • Competition from other menin inhibitors (e.g., Syndax's revumenib) could limit market share
  • Differentiation syndrome boxed warning may constrain prescriber adoption
  • Phase 3 KOMET-017 trial results not expected until 2028, creating binary event risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-219422
Document: kura-20260512.htm0001193125-26-219422
Document: 0001193125-26-219422-index-headers.html0001193125-26-219422
Document: 0001193125-26-219422-index.html0001193125-26-219422
Document: 0001193125-26-219422.txt0001193125-26-219422
8-K Data (Synthetic)0001193125-26-219422

Track record

29 reports on KURA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026